Literature DB >> 334188

[New antihypertensive agent of the imidazoline series: 5-fluoro-methyl-imidazolidinylidene-benzamine-monohydrochloride (flutonidin)].

H Brunner, S Djawan, W Dorda, E Penner, G Grabner.   

Abstract

A New Antihypertensive of the Imidazoline Series: 5-Fluoro-2-methyl-imidazolidinylidene-benzamine-monohydrochloride. 5-Fluoro-2-methyl-imidazolidinylidene-benzamine-hydrochloride (flutonidin, ST 600), a new antihypertensive imidazoline compound, was tested over 3 weeks in 20 patients with moderate to severe hypertension. Blood pressure was significantly lowered in both supine and upright position. In nearly 2/3 of the patients treated normalization of blood pressure was achieved. Side effects like sedation, dry mouth or orthostatic complaints were present in 30%. Toxic effects were not registered. It is recommended to reduce the dosage slowly especially in the aged to prevent, in part severe findings after abrupt withdrawal.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 334188

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Differences in psychic performance with guanfacine and clonidine in normotensive subjects.

Authors:  J Kugler; R Seus; R Krauskopf; H M Brecht; A Raschig
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

2.  Hypotensive action and side-effects of flutonidin in normal subjects. A double-blind controlled trial.

Authors:  P Sala; S M Chierichetti; P Ferrari
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.